FEATURED EDITORIAL
There are 100,000+ venomous animal species, each producing a chemical cocktail of up to 1,000 different components, including peptides, proteins, and non-peptide small molecules. Many in drug development view venom-derived compounds as simple peptides that will be easily digested, limiting their therapeutic potential. This article dispels that myth.
- Your 3-Step Process For Innovation In Precision Medicine
- Data: The Near Future Of Regulatory Info Management In Europe
- Can Molecular Modeling Overcome The Limitations Of Drug Discovery AI?
- Nonprofit Drug Development: An Innovative Solution To Advancing Treatments For Rare Genetic Diseases
- FDA Seeks Comment On ICH Q9(R1) Quality Risk Management
- Market Tumult And The Need For Creative Funding For Life Sciences
- Mold Investigations Using Biofluorescent Particle Counting Systems
FEATURED APPLICATION CONTENT
-
A leading biotech company working in the targeted protein degradation space was looking for fast delivery of the compounds, open, transparent and on-time communication, and flexibility and ability to scale.
-
Explore our best practices for apheresis collection and obtention of enriched product for cell therapies.
-
Discover how we automate the optimizing cell harvesting process and further minimize the potential for cell loss during wash steps.
-
Follow the feasibility of xeno‑free NK cell expansion, closure of key unit operations, and how future work could focus on fine‑tuning each step to generate a robust, scalable process.
-
Using a model T-cell line, we demonstrate the impact of varying rinse volume, intermediate volume, and manual extraction parameters on overall cell recovery with a final product dose volume of 20 mL.
-
Single-pass TFF technology brings practical and economic advances to TFF by simplifying the process and creating new capabilities.
-
Explore how surface plasmon resonance (SPR)-based analyses with a high sensitivity instrument can provide greater data precision and better confidence in your results interpretation.
-
Explore how you can simplify research on protein-protein interactions using our SPR systems.
-
When considering the manufacturing of gene therapy vectors or recombinant vaccines, selection of the most appropriate technology is key. Here we review a powerful and flexible platform for DNA transfection.
-
A review of high-conentration mAb manufacturing challenges including viscosity, aggregation, instability, and the effect of excipients on formulation, filtration, and fill and finish and bioavailability.
-
This study examines a QTOF system that can collect high-resolution, high mass accuracy, full-scan MS and MS/MS data.
-
Three combination case studies are demonstrated, in which bevacizumab is paired with erlotinib, cisplatin, or paclitaxel in a dry powder inhaler formulation.
FEATURED NEWS HEADLINES
- AbCellera And Atlas Venture Collaborate To Empower The Development Of Impactful Medicines For Patients
- SpectrumX Partners With Leading UK Specials Group To Accelerate Production Of Anti-Pathogenic Drug For Clinical Trials
- Sumitomo Pharma Oncology Receives Orphan Drug Designation For DSP-5336, An Investigational Menin And Mixed-Lineage Leukemia Binding Protein For Treatment Of Acute Myeloid Leukemia
- H1 And Lokavant Partner On Data And Analytics To Power Next Generation Clinical Trials
- Rice Lab’s ‘Drug Factory’ Implants Cleared For Human Trials
- Artisan Launches STAR-CRISPR™ To Provide Broad Gene Editing Access For Drug Discovery And Development
- MAIA Biotechnology Receives FDA Orphan Drug Designation For THIO For The Treatment Of Small-Cell Lung Cancer (SCLC)
- Synthego Launches Engineered Cell Libraries To Validate Targets With Speed And Accelerate Drug Discovery
- Tavanta Therapeutics Announces Completion Of Enrollment In Pivotal Phase 3 Trial Of TAVT-45 For The Treatment Of Metastatic Prostate Cancer
- Sosei Heptares And AbbVie Enter New Multi-Target Collaboration To Discover, Develop And Commercialize Novel Medicines Targeting Neurological Diseases
ARCHIVED NEWSLETTER
- 08.09.22 -- Reshaping Supply Chains In Response To COVID-19
- 08.09.22 -- A Look Into The Future Of Bioprocessing
- 08.08.22 -- Inside Gamma Delta T Cells, Innate Immunity & Mouse Models, and more podcast episodes!
- 08.02.22 -- Rapid Method Development: Overcome Bispecific Antibody Purification Challenges
- 08.02.22 -- How Collaborative Value Engineering And Continuous Improvement Enhance The CDMO Relationship